Positions

Overview

  • Julie Kanter, MD is the director of the UAB Adult Sickle Cell Clinic and associate professor in the Division of Hematology and Oncology. Her clinical and research interests in sickle cell disease include improving access to care for affected individuals, and identifying and developing novel therapies for sickle cell disease, as well as enhancing horizontal care for patients with sickle cell disease. Kanter comes to UAB from the Medical University of South Carolina, where she was director of sickle cell disease research. Kanter also co-directs the UAB Comprehensive Sickle Cell Disease Center.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Multi-organ Dysfunction Secondary to Abrupt Discontinuation of Voxelotor in a Patient with Severe Sickle Cell Disease.American Journal of Hematology2022
    2022 Pregnancy outcomes with hydroxyurea use in women with sickle cell diseaseAmerican Journal of Hematology.  97:603-612. 2022
    2022 Perspectives of individuals with sickle cell disease on barriers to carePLoS ONE.  17. 2022
    2022 Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority studyBlood Advances.  6:1243-1254. 2022
    2022 Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell DiseaseNew England Journal of Medicine.  386:617-628. 2022
    2022 GRNDaD: big data and sickle cell disease.Blood Adv.  6:1088. 2022
    2022 Acute myeloid leukemia case after gene therapy for sickle cell diseaseNew England Journal of Medicine.  386:138-147. 2022
    2022 Confirmation of the utility of the Wells’ Score for pulmonary embolism in patients with sickle cell diseaseJournal of Thrombosis and Thrombolysis2022
    2021 Association Between Patent Foramen Ovale and Overt Ischemic Stroke in Children With Sickle Cell DiseaseFrontiers in Neurology.  12. 2021
    2021 Gene therapy for sickle cell disease: where we are now?Hematology online (ASH).  2021:174-180. 2021
    2021 Gaps in the diagnosis and management of iron overload in sickle cell disease: a ‘real-world’ report from the GRNDaD registryBritish Journal of Haematology.  195:e157-e160. 2021
    2021 Identifying barriers to evidence-based care for sickle cell disease: Results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USABMJ Open.  11. 2021
    2021 Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab studyBritish Journal of Haematology.  195:e150-e153. 2021
    2021 Which adults with sickle cell disease need an evaluation for pulmonary embolism?British Journal of Haematology.  195:447-455. 2021
    2021 Annals On Call - Vascular Occlusive Crisis: Site of Care MattersAnnals of Internal Medicine.  174:OC1. 2021
    2021 Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation ConsortiumPLoS ONE.  16. 2021
    2021 American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantationBlood Advances.  5:3668-3689. 2021
    2021 One small step for sickle cell disease: Many more to goAnnals of Internal Medicine.  174:1313-1314. 2021
    2021 Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease 2021
    2021 Kneeling was the first step for sickle cell diseaseAnnals of Internal Medicine.  174:1004-1005. 2021
    2021 For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports 2021
    2021 Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults with Sickle Cell Disease: A Randomized Clinical Trial 2021
    2021 Feasibility of an mHealth self-management intervention for children and adolescents with sickle cell disease and their familiesTranslational Behavioral Medicine.  11:724-732. 2021
    2021 Definity, an affinity for painful crisis: a case series describing vaso-occlusive pain crises in sickle cell patients undergoing echocardiogram with Definity contrast 2021
    2021 Emergency department utilization for sickle cell disease in st. Vincent and the grenadinesPan African Medical Journal.  38. 2021
    2021 Transcranial doppler screening in a current cohort of children with sickle cell anemia: Results from the DISPLACE StudyJournal of Pediatric Hematology/Oncology2021
    2021 Treatment-related correlates of growth in children with sickle cell disease in the DISPLACE cohortJournal of Pediatric Hematology/Oncology2021
    2020 Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium 2020
    2020 A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency DepartmentAnnals of Emergency Medicine.  76:S64-S72. 2020
    2020 Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trialAmerican Journal of Hematology.  95:E239-E242. 2020
    2020 Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspectsBlood Advances.  4:3804-3813. 2020
    2020 Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell diseaseBlood.  136:623-626. 2020
    2020 Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registryOrphanet Journal of Rare Diseases.  15. 2020
    2020 Perceptions of US Adolescents and Adults with Sickle Cell Disease on Their Quality of CareJAMA Network Open.  3. 2020
    2020 Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell diseaseBlood Advances.  4:2058-2063. 2020
    2020 Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium 2020
    2020 An unusual ultrasound appearance of renal hemosiderosis in acute sickle cell nephropathyRadiology Case Reports.  15:26-30. 2020
    2020 Changes in Care Delivery for Children with Sickle Cell Anemia during the COVID-19 PandemicJournal of Pediatric Hematology/Oncology2020
    2020 Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic Advances in Hematology.  11:2040620720955000. 2020
    2020 Development of a severity classification system for sickle cell diseaseClinicoEconomics and Outcomes Research.  12:625-633. 2020
    2020 Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell DiseaseClinical Pharmacology and Therapeutics.  107:140-146. 2020
    2019 An approach to revising mHealth interventions for children and families: A case example in sickle cell diseaseResearch in Nursing and Health.  42:483-493. 2019
    2019 International differences in outpatient pain management: A survey of sickle cell diseaseJournal of Clinical Medicine.  8. 2019
    2019 Ischemic stroke in children and young adults with sickle cell disease in the post-STOP eraAmerican Journal of Hematology.  94:1335-1343. 2019
    2019 Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort studyLancet Haematology.  6:e585-e596. 2019
    2019 Diagnosis of Hemoglobin M Disease in a Toddler Presenting With Hypoxemia and HemolysisClinical Pediatrics.  58:1345-1348. 2019
    2019 Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3)Contemporary Clinical Trials.  85. 2019
    2019 A Phase 3 randomized trial of voxelotor in sickle cell diseaseNew England Journal of Medicine.  381:509-519. 2019
    2019 Health-related Quality of Life in Children with Sickle Cell Disease Undergoing Chronic Red Cell Transfusion TherapyJournal of Pediatric Hematology/Oncology.  41:307-312. 2019
    2019 Childhood Hearing Loss in Patients With Sickle Cell Disease in the United StatesJournal of Pediatric Hematology/Oncology.  41:124-128. 2019
    2019 Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemiaBritish Journal of Haematology.  184:1058-1061. 2019
    2019 Barriers to Pediatric Sickle Cell Disease Guideline RecommendationsGlobal Pediatric Health.  6. 2019
    2019 Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysisAmerican Journal of Hematology.  94:55-61. 2019
    2019 Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb studyBritish Journal of Haematology.  184:269-278. 2019
    2018 The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell diseaseAmerican Journal of Hematology.  93:E391-E395. 2018
    2018 The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell AnemiaJournal of Stroke and Cerebrovascular Diseases.  27:2897-2904. 2018
    2018 Opioid utilization patterns in United States individuals with sickle cell diseaseAmerican Journal of Hematology.  93:E345-E347. 2018
    2018 Incomplete implementation of guideline-based stroke prevention therapy in sickle cell diseaseAmerican Journal of Hematology.  93:E222-E224. 2018
    2018 Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)Blood Advances.  2:1969-1979. 2018
    2018 A phase 3 trial of l-glutamine in sickle cell diseaseNew England Journal of Medicine.  379:226-235. 2018
    2018 Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort studyJournal of Thrombosis and Thrombolysis.  45:512-515. 2018
    2018 Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series 2018
    2018 CrizanlizumabDrugs of the future.  43:489-499. 2018
    2017 Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases 2017
    2017 Crizanlizumab in sickle cell diseaseNew England Journal of Medicine.  376:1795-1796. 2017
    2017 Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings from Get with the Guidelines-StrokeStroke.  48:686-691. 2017
    2017 Crizanlizumab for the prevention of pain crises in sickle cell diseaseNew England Journal of Medicine.  376:429-439. 2017
    2017 Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and strokeBritish Journal of Haematology.  176:300-308. 2017
    2017 Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening ProgramGlobal Pediatric Health.  4. 2017
    2017 Prevalence of sickle cell disease among newborns in St Vincent and the Grenadines: A retrospective studyWest Indian Medical Journal.  66:486-490. 2017
    2017 Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemiaThrombosis and Haemostasis.  117:580-588. 2017
    2016 Transcranial doppler re-screening of subjects who participated in STOP and STOP IIAmerican Journal of Hematology.  91:1191-1194. 2016
    2016 Assessing the immunogenic response of a single center's pneumococcal vaccination protocol in sickle cell diseaseJournal of Pediatric Hematology/Oncology.  38:e102-e106. 2016
    2016 A multinational trial of prasugrel for sickle cell vaso-occlusive eventsNew England Journal of Medicine.  374:625-635. 2016
    2016 Validation of a low-cost paper-based screening test for sickle cell anemiaPLoS ONE.  11. 2016
    2016 Needs assessment for patients with sickle cell disease in South Carolina, 2012Public Health Reports.  131:108-116. 2016
    2015 Validation of a novel point of care testing device for sickle cell diseaseBMC Medicine.  13. 2015
    2015 Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trialBiology of Blood and Marrow Transplantation.  21:900-905. 2015
    2015 Multicenter COMPACT study of COMplications in Patients with sickle cell disease and utilization of iron Chelation TherapyCurrent Medical Research and Opinion.  31:513-523. 2015
    2015 When is the optimal time to screen for chlamydia in adolescents and young adults with sickle cell disease?Clinical Pediatrics.  54:149-151. 2015
    2015 Prasugrel in children with sickle cell disease: Pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging studyJournal of Pediatric Hematology/Oncology.  37:1-9. 2015
    2014 Density-based separation in multiphase systems provides a simple method to identify sickle cell disease 2014
    2014 A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyureaJournal of Pediatric Hematology/Oncology.  36. 2014
    2013 A case of invasive Streptococcus pneumoniae in an afebrile adolescent with sickle cell diseaseClinical Pediatrics.  52:1173-1175. 2013
    2013 Management of sickle cell disease from childhood through adulthoodBlood Reviews.  27:279-287. 2013
    2013 A simple, rapid, low-cost diagnostic test for sickle cell disease 2013
    2013 Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab 2013
    2013 Simple paper-based test for measuring blood hemoglobin concentration in resource-limited settings. 2013
    2012 Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood.  119:5989-5995. 2012
    2011 Posterior fossa syndrome after surgical removal of a pineal gland tumorPediatric Neurology.  45:417-419. 2011
    2011 A child with Wegener's granulomatosis and severe hemophilia A: Interplay of disease processesClinical Pediatrics.  50:767-771. 2011
    2009 Downsizing to resectabilty of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapyJournal of Pediatric Surgery.  44. 2009
    2008 Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentratesClinical Cancer Research.  14:3942-3947. 2008

    Principal Investigator On

  • 1/2 Sickle Cell Disease and CardioVascular Risk-Red Cell Exchange Trial (SCDCARRE Trial)  awarded by University of Pittsburgh The
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ALSTATE (Alabama Lifespan Sickle Cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ALSTATE (Alabama Lifespan Sickle Cell Tracking Access Towards Equality) Network  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Continuous Quality Improvement (CQI) for Sickle Cell Disease Newborn Screening follow-up  awarded by Association of Public Health Laboratories
  • DISPLACE: Dissemination and Implementation of Stroke Prevention Looking at the Care Environment  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Hydroxyurea Pharmacokinetics and Pharmacodynamics in Adults with Sickle Cell Anemia  awarded by CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)
  • Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC)  awarded by Medical University of South Carolina
  • Patient Characteristics and Treatment Patterns from Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis from Select Sickle Cell Centers  awarded by NATIONAL ALLIANCE OF SICKLE CELL CENTERS
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by IMARA INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by CYCLERION THERAPEUTICS INC
  • Private Grant  awarded by BAXALTA US INC.
  • Private Grant  awarded by TAUTONA RESEARCH AND DEVELOPMENT COMPANY LLC
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by IMARA INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by GRAPHITE BIO
  • Private Grant  awarded by FORMA THERAPEUTICS
  • Private Grant  awarded by VIFOR
  • Sickle Cell Disease and Cardiovascular Risk-Red Cell Exchange Trial (SCD-CARRE)  awarded by University of Pittsburgh The
  • Sickle Cell Treatment Demonstration Program  awarded by Health Resources and Services Administration/DHHS
  • Sickle Cell Treatment Demonstration Program - EMBRACE  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Education And Training

  • Doctor of Medicine, Tulane University 2004
  • Bachelor of Arts in Biology, Washington University/St. Louis 1999
  • Full Name

  • Julie Kanter